Study design and patient characteristics
cancer, death, tumour, Cancer
CANCER, SOLID TUMOUR, TUMOUR, CANCER
We conducted a retrospective review of patients with solid tumours participating in Phase I studies at the National University Cancer Institute, Singapore (NCIS) between October 2013 and December 2020. Patients enrolled in the studies fulfilled the eligibility criteria of the respective studies. Patient demographics, cancer and treatment history, clinical parameters including components of the RMH score and NLR ratio, tumour molecular information and date of death or last follow-up were retrieved from the electronic medical records between October 2013 and December 2020. The RMH score evaluates serum albumin (<35 g/dL constitutes 1 point), number of metastatic sites (3 or more sites constitute 1 point) and serum LDH (more than one-time upper limit normal constitutes 1 point); with scores 0–1 and 2–3 connoting good and poor prognosis, respectively. NLR ratio is calculated by dividing first encounter serum neutrophil count by serum lymphocyte count. The study was approved by the institutional review board.